United Therapeutics

UTHR · NASDAQ

$553.88+$10.73 (+1.98%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $543.15

UTHR analyst rating

BuyConsensus of 13 analysts over the last 12 months. 77% rate it a buy.

Strong buy0
Buy10
Hold2
Underperform0
Sell1

12-month price target · 18 analysts

Average $648.03 (+17.0% upside)

Low: $324.21
Now: $553.88
High: $764.40

Upgrades and downgrades

The latest rating actions, newest first

UTHR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Leerink Partners	Oct 19, 2026	Maintains	Outperform	$685.00 → $725.00	35%
RBC Capital	Oct 8, 2026	Maintains	Outperform	$677.00 → $708.00	44%
Morgan Stanley	Oct 7, 2026	Maintains	Equal-Weight	$515.00 → $566.00	63%
BTIG	Oct 1, 2026	Upgrade	Neutral → Buy	$728.00	34%
Goldman Sachs	Sep 24, 2026	Initiates	Sell	$321.00	42%
RBC Capital	Aug 6, 2026	Maintains	Outperform	$704.00 → $677.00	44%
JP Morgan	Jul 23, 2026	Maintains	Overweight	$685.00 → $687.00	57%
B of A Securities	Jul 10, 2026	Maintains	Neutral	$620.00 → $613.00	57%
RBC Capital	Jul 7, 2026	Maintains	Outperform	$701.00 → $704.00	44%
RBC Capital	May 7, 2026	Maintains	Outperform	$707.00 → $701.00	44%

The case for and against

Updated Aug 18, 2026

Bull case

United Therapeutics is poised for long-term growth due to its strong focus on the prostacyclin pathway for treating PAH and its market-leading position in this disease space. The company's diverse portfolio of commercialized products and ongoing research in new indications such as IPF and PH-ILD, as well as its plans to launch the treprostinil soft mist inhaler, show potential for continued success. Furthermore, the company's impressive financial results and favorable response from key opinion leaders in the field of PAH bode well for its future growth and positioning as a key player in the PAH market.

Bear case

United Therapeutics is facing potential limitations in its market expansion plans, as discussions around expanding Tyvaso into IPF are influenced by uncertainty around the drug's antifibrotic activity versus its treatment of accompanying pulmonary vascular disease. Additionally, while there is potential for Tyvaso to address a broad IPF treatment role, the company faces significant competition in this market as well as potential regulatory challenges. Given these factors, the company's stock may struggle in the long term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.